The Resource Multiple sclerosis therapeutics, editors, Jeffrey A. Cohen, Richard A. Rudick

Multiple sclerosis therapeutics, editors, Jeffrey A. Cohen, Richard A. Rudick

Label
Multiple sclerosis therapeutics
Title
Multiple sclerosis therapeutics
Statement of responsibility
editors, Jeffrey A. Cohen, Richard A. Rudick
Contributor
Subject
Language
eng
Summary
Provides comprehensive information on clinical trial methodology and therapeutic modalities in multiple sclerosis. This edition reflects the advances in understanding of the pathophysiology of the disease. It also includes chapters on biomarkers in MS, pharmacogenomics, emerging therapeutic modalities, neuroprotection, and the use of OCT and MRI
Cataloging source
N$T
Dewey number
616.83406
Illustrations
illustrations
Index
index present
LC call number
RA645.M82
LC item number
M85 2007eb
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
Label
Multiple sclerosis therapeutics, editors, Jeffrey A. Cohen, Richard A. Rudick
Publication
Note
Previous edition: London : Martin Dunitz, 2002
Antecedent source
unknown
Bibliography note
Includes bibliographical references and index
http://library.link/vocab/branchCode
  • net
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
Introduction. Aspects of multiple sclerosis that relate to trial design and clinical management. Biological concepts of multiple sclerosis pathogenesis and relationship to treatment. The multiple sclerosis disease process as characterized by magnetic resonance imaging -- Clinical trial methodology. Measures of neurological impairment and disability in multiple sclerosis. Health-related quality of life assessment in multiple sclerosis. Measures of gadolinium enhancement, T1 black holes and T2-hyperintense lesions on magnetic resonance imaging in multiple sclerosis. Measures of magnetization transfer in multiple sclerosis. Measurement of central nervous system atrophy in multiple sclerosis. Axonal pathology in patients with multiple sclerosis. Functional imaging in multiple sclerosis. Magnetic resonance imaging of pathway-specific structure and function in multiple sclerosis. Optical coherence tomography to monitor neuronal integrity in multiple sclerosis. Biomarkers in multiple sclerosis. The process of drug development and approval in the United States, the European Union, and Canada. Selection and interpretation of end-points in multiple sclerosis clinical trials. Clinical trial logistics. The challenge of long-term studies in multiple sclerosis: use of pooled data, historical controls, and observational studies to determine efficacy. Alternative designs for multiple sclerosis clinical trials. Ethical considerations in multiple sclerosis clinical trials. Pharmacogenetics and phamacogenomics in multiple sclerosis -- Clinical trials of multiple sclerosis therapies. Interferons in relapsing-remitting multiple sclerosis. Interferons in secondary progressive multiple sclerosis. Neutralizing antibodies directed against interferon [beta]. Glatiramer acetate as therapy for multiple sclerosis. Use of mitoxantrone to treat multiple sclerosis. Use of cyclophosphamide and other immunosuppressants to treat multiple sclerosis. Natalizumab in multiple sclerosis. High-dose methylpredisolone in the treatment of multiple sclerosis. Intravenous immunoglobulin in multiple sclerosis. Therapeutic plasma exchange for multiple sclerosis. Statins in multiple sclerosis. Stem cell transplantatation for multiple sclerosis. T cell-based therapies for multiple sclerosis and related diseases. Chemokines and central nervous system inflammation: relevance to multiple sclerosis. Sex hormones and other pregnancy-related factors with therapeutic potential in multiple sclerosis. Neuroprotection in multiple sclerosis. Combination therapy in multiple sclerosis. Fampridine in multiple sclerosis. Complementary and alternative treatments in multiple sclerosis -- Therapy in clinical practice. Disease-modifying therapy for multiple sclerosis in clinical practice. Treatment for patients with primary progressive multiple sclerosis. Use of magnetic resonance imaging in clinical management of multiple sclerosis. Fatigue in multiple sclerosis. Management of spasticity in multiple sclerosis. Management of bladder and sexual dysfunction in multiple sclerosis. Depression in multiple sclerosis. Treatment of pain, paresthesias, and paroxysmal disorders in multiple sclerosis. Rehabilitation in multiple sclerosis patients
Control code
ocn183413709
Dimensions
unknown
Edition
3rd ed
Extent
1 online resource (xxxi, 896 pages)
File format
unknown
Form of item
online
Isbn
9780203012055
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
c
Other physical details
illustrations
Quality assurance targets
not applicable
http://library.link/vocab/recordID
.b24466554
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
  • (OCoLC)183413709
  • pebco0203012054

Library Locations

    • Deakin University Library - Geelong Waurn Ponds CampusBorrow it
      75 Pigdons Road, Waurn Ponds, Victoria, 3216, AU
      -38.195656 144.304955
Processing Feedback ...